Karen Reckamp named medical director for clinical research at City of Hope

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

KAREN RECKAMP was named medical director for clinical research operations at City of Hope.

In this newly created position, Reckamp will expand her current role as chair of the Cancer Protocol Review and Monitoring Committee. She will also serve as medical director of the Clinical Trials Unit and as coordinating liaison for pharmaceutical contracts, as well as share responsibility for the review and selection of clinical trials within City of Hope.

Reckamp is also co-chair of the institution’s Lung Cancer and Thoracic Oncology Program. She is currently principal investigator for an arm of the NCI-MATCH trial.

Reckamp joined City of Hope in 2007, as assistant professor of medicine in the Department of Medical Oncology & Therapeutics. In 2012, she became associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Lung Cancer and Thoracic Oncology Program.

She received her medical doctorate from the University of Chicago Pritzker School of Medicine, and her Master of Science degree from the University of California, Los Angeles, where she also received specialized training in advanced research and clinical research. She completed a fellowship in hematology/oncology at UCLA, and an internship and residency at Barnes-Jewish Hospital in St. Louis.

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login